Sign in Subscribe
COVID-19 vaccines

AstraZeneca's New Medicine Approved for Scotland's Leukaemia Patients

Strategic Insights

— 1 min read

AstraZeneca has secured crucial approval for a revolutionary new medicine that will greatly improve the lives of Scots cancer patients with the most common form of leukaemia. The Scottish Medicines Consortium has greenlit acalabrutinib, an oral pill that can be taken at home, which targets the disease while minimizing debilitating side effects. This groundbreaking treatment will significantly reduce the burden of chemotherapy, enabling leukaemia patients to maintain a better quality of life, work, and family life.

Key Takeaways:

  • AstraZeneca's acalabrutinib has been approved by the Scottish Medicines Consortium for the treatment of chronic lymphocytic leukaemia (CLL) patients in Scotland.
  • The new medicine targets the disease and has fewer side effects compared to traditional chemotherapy, which often requires hospital infusions and leaves patients feeling "pretty rough" and disrupting their work and family life.
  • CLL patient John Greensmyth, a trustee at the CLL Support group, believes the new pill form treatment will greatly improve the lives of people living with CLL, allowing them to avoid gruelling chemotherapy infusions.
  • According to John Greensmyth, the new treatment has fewer side effects, particularly fatigue, but is still significantly better tolerated than chemotherapy.
  • Approximately 260 people are diagnosed with CLL every year in Scotland, and 1,000 people are living with the disease, with 41% of them aged 75 and over.
  • CLL patients were advised to shield throughout the lockdowns but are now benefiting from the success of vaccines, including AstraZeneca's, which has improved their immunocompromised status.
  • Dr. Mark Rafferty, Consultant Haematologist at the Beatson West of Scotland Cancer Centre, stated that the availability of acalabrutinib through NHS Scotland has the potential to improve disease outcomes for many patients with CLL.

Statistics:

  • Approximately 1,000 people are living with CLL in Scotland.
  • 41% of CLL patients in Scotland are aged 75 and over.
  • AstraZeneca's acalabrutinib targets CLL patients with significantly fewer side effects compared to traditional chemotherapy.
  • CLL patients experienced a 30% protection rate after the first vaccine and 70% after the second vaccine.
  • AstraZeneca has a recent track record of developing life-changing medications that greatly improve the lives of cancer patients in Scotland.

Sources:

*

The Scottish Medicines Consortium

CLL Support group

John Greensmyth's personal experience and quotes

Dr. Mark Rafferty's expertise and quotes

matt.bendoris@the-sun.co.uk

Read more